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Nepafenac ophthalmic suspensions, 0.1% (NEVANAC®) and 0.3% (ILEVRO™), are topical nonsteroidal anti-
inﬂammatory drug (NSAID) products approved in the United States, Europe and various other countries
to treat pain and inﬂammation associated with cataract surgery. NEVANAC is also approved in Europe for
the reduction in the risk of postoperative macular edema (ME) associated with cataract surgery in
diabetic patients. The efﬁcacy against ME suggests that topical administration leads to distribution of
nepafenac or its active metabolite amfenac to the posterior segment of the eye. This article evaluates the
ocular distribution of nepafenac and amfenac and the extent of local delivery to the posterior segment of
the eye, following topical ocular instillation in animal models. Nepafenac ophthalmic suspension was
instilled unilaterally in New Zealand White rabbits as either a single dose (0.1%; one drop) or as multiple
doses (0.3%, one drop, once-daily for 4 days, or 0.1% one drop, three-times daily for 3 days and one
morning dose on day 4). Nepafenac (0.3%) was also instilled unilaterally in cynomolgus monkeys as
multiple doses (one drop, three-times daily for 7 days). Nepafenac and amfenac concentrations in har-
vested ocular tissues were measured using high-performance liquid chromatography/mass spectrom-
etry. Locally-distributed compound concentrations were determined as the difference in levels between
dosed and undosed eyes. In single-dosed rabbit eyes, peak concentrations of locally-distributed nepa-
fenac and amfenac showed a trend of sclera > choroid > retina. Nepafenac peak levels in sub-samples
posterior to the eye equator and inclusive of the posterior pole (E-PP) were 55.1, 4.03 and 2.72 nM,
respectively, at 0.25 or 0.50 h, with corresponding amfenac peak levels of 41.9, 3.10 and 0.705 nM at 1 or
4 h. By comparison, peak levels in sclera, choroid and retina sub-samples in a band between the ora
serrata and the equator (OS-E) were 13- to 40-fold (nepafenac) or 11- to 23-fold (amfenac) higher,
indicating an anterior-to-posterior directional concentration gradient. In multiple-dosed rabbit eyes,
with 0.3% nepafenac instilled once-daily or 0.1% nepafenac instilled three-times daily, cumulative 24-
h locally-distributed levels of nepafenac in E-PP retina were similar between these groups, whereas
exposure to amfenac once-daily dosing nepafenac 0.3% was 51% of that achieved with three-times daily
dosing of 0.1%. In single-dosed monkey eyes, concentration gradients showed similar directionality as
observed in rabbit eyes. Peak concentrations of locally-distributed nepafenac were 1580, 386, 292 and
13.8 nM in E-PP sclera, choroid and retina, vitreous humor, respectively, at 1 or 2 h after drug instillation.
Corresponding amfenac concentrations were 21.3, 11.8, 2.58 and 2.82 nM, observed 1 or 2 h post-
instillation. The data indicate that topically administered nepafenac and its metabolite amfenac reach
pharmacologically relevant concentrations in the posterior eye segment (choroid and retina) via local
distribution, following an anterior-to-posterior concentration gradient. The proposed pathway involves a
choroidal/suprachoroidal or periocular route, along with an inward movement of drug through theperformance liquid chroma-
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concentrations in posterior segment tissues may be a reservoir for hydrolysis to amfenac.
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Nepafenac ophthalmic suspension, 0.1% (NEVANAC®; Alcon
Research, Ltd., Fort Worth, TX) and 0.3% (ILEVRO™, Alcon Research,
Ltd., Fort Worth, TX) are topical ocular nonsteroidal anti-
inﬂammatory drug (NSAID) products approved in the United
States, Europe and various other countries for the treatment of pain
and inﬂammation associated with cataract surgery (Lane et al.,
2007; NEVANAC® Prescribing Information; ILEVRO™ Prescribing
Information). NEVANAC is also approved in Europe for the reduc-
tion in the risk of postoperative ME associated with cataract sur-
gery in diabetic patients (NEVANAC Summary of Product
Characteristics). Studies in various animal models of inﬂammation,
edema, and angiogenesis have shown nepafenac to be effective
after topical ocular administration (Gamache et al., 2000; Kapin
et al., 2003; Kern et al., 2007; Takahashi et al., 2003). Moreover,
clinical studies have shown nepafenac 0.1% to be effective in the
management of ME secondary to cataract extraction in diabetics
(Hariprasad et al., 2007; Singh et al., 2012; Warren and Fox, 2008;
Wolf et al., 2007).
Unlike other NSAIDs, nepafenac has prodrug properties and is
deaminated in ocular tissues to an active free arylacetic acid analog,
amfenac (2-amino-3-benzoylbenzeneacetic acid) (Ke et al., 2000;
Walters et al., 2007). Nepafenac and amfenac are both reversible
inhibitors of the cyclooxygenase (COX) enzymes COX-1 and COX-2,
while amfenac also potently inhibits both isoforms, especially COX-
2, in an essentially irreversible manner (Gamache et al., 2000;
Kulmacz and Graff, 2007; Walters et al., 2007). The inhibition of
COX enzyme activity blocks the formation of various proin-
ﬂammatory mediators, including the prostaglandins, which have
been linked to the disruption of the blood-aqueous barrier and the
increase in vascular permeability changes that are associated with
inﬂammation and edema (Flach, 1992; Smyth and FitzGerald,
2007). Inhibition of prostaglandin synthesis and vascular leakage
has been demonstrated by Kapin et al. (2003) following adminis-
tration of topical ocular nepafenac.
In vitro and ex vivo studies have shown nepafenac to rapidly
permeate the cornea and sclera, and to be converted by amidases to
amfenac, primarily in the iris-ciliary body (ICB) and retina/choroid
(Ke et al., 2000). It is important to note that ICB also contains the
highest prostaglandin concentrations and COX activity, and levels
of these in the retina, while lower, are still meaningful (Kulkarni
and Srinivasan, 1989; Radi and Render, 2008). Nepafenac may,
therefore, have prolonged activity in these ocular tissues due to its
subsequent conversion to active amfenac (Warren and Fox, 2008).
Pharmacodynamic results involving the retina from preclinical
and clinical studies (Lindstrom and Kim, 2006; Singh et al., 2012)
provide evidence to suggest that nepafenac and/or amfenac reach
the retina, and perhaps other posterior-segment tissues, i.e. choroid
and vitreous humor, after topical administration of nepafenac. In
further support, Bucolo et al. (2014) reported that topical nepafenac
in a rat lipopolysaccharide-induced uveitis model was effective in
decreasing retinal prostaglandin (PGE2) levels, although to a lesser
extent than indomethacin or bromfenac. Despite the pharmaco-
dynamic evidence, the extent of local drug delivery and the dis-
tribution pathway(s) have not been well characterized. Therefore,
the primary purpose of the studies described in this article was to
evaluate the contribution of local topical ocular delivery to thebioavailability of nepafenac and amfenac in the posterior segment,
and to expand the understanding of potential distribution path-
ways of these molecules to the posterior segment tissues of the eye.
The biodistribution of nepafenac and amfenac was evaluated after
single or repeated unilateral topical ocular doses of nepafenac
ophthalmic suspension in rabbit and monkey models.
2. Material and methods
2.1. Animals and housing conditions
All aspects of the animal studies, including housing and
handling, conformed to the Association for Research in Vision and
Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmic and Vision Research, as well as Alcon's Animal Care and
Use Committee Guidelines.
Male New Zealand white (NZW) rabbits were obtained from
Myrtle's Rabbitry (Thompsons Station, TN). The rabbits were indi-
vidually housed in a temperature- and humidity-controlled envi-
ronment with 12-h light/dark cycles. Normal laboratory diet was
available ad libitum and the rabbits were euthanized with sodium
pentobarbital (Sleepaway®, Fort Dodge, IA).
The monkey study was conducted at Charles River Laboratories
(CRL), Worchester, MA. Male cynomolgus monkeys (weight,
2.5e5.0 kg) were obtained from the CRL test facility colonies. The
animals were individually housed in temperature- and humidity-
controlled rooms with 12-h light/dark cycles. The animals were
fed certiﬁed primate chow twice daily with water, washed fresh
fruit, and produce; feeding was ad libitum. The monkeys were
euthanized with sodium pentobarbital prior to ocular tissue
sampling.
2.2. Test articles
Nepafenac 0.1% ophthalmic suspension was prepared in carbo-
pol 974P, 0.005% benzalkonium chloride (preservative), tyloxapol,
mannitol, edetate disodium and sodium chloride vehicle by Alcon
Research, Ltd. (Fort Worth, TX). Nepafenac 0.3% was prepared in
carbopol 974P, 0.005% benzalkonium chloride (preservative), boric
acid, propylene glycol, guar gum, carboxy methylcellulose, edetate
disodium and sodium chloride vehicle by Alcon Research, Ltd. (Fort
Worth, TX). The concentrations of excipients in these test
ophthalmic suspensions of nepafenac were identical to the
commercially available NEVANAC or ILEVRO preparations. ILEVRO
and NEVANAC formulation characteristics are different in that
ILEVRO has a proprietary viscosity system designed to enhance
ocular retention and contribute to increased nepafenac
bioavailability.
2.3. Study designs
2.3.1. Ocular distribution study: rabbits
For the single dosing study, a single 30-mL drop of nepafenac
0.1% ophthalmic suspension was instilled in the cul-de-sac of the
right eye of male NZW rabbits. In total, 36 animals were euthanized
(four at each time point) at 0.25, 0.5, 1, 2, 4, 8, 12, 24, and 48 h post-
dose. Blood samples were obtained for the measurement of nepa-
fenac and amfenac plasma concentrations immediately prior to
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the dosed and fellow undosed eyes from each animal were
enucleated and dissected.
For the multiple dosing study: i) one 30-mL drop of nepafenac
0.3% ophthalmic suspension was instilled in the cul-de-sac of the
right eye of 32 male NZW rabbits once-daily (QD) for 4 days; ii) one
30-mL drop of nepafenac 0.1% ophthalmic suspension was instilled
in the cul-de-sac of the right eye of 32 male NZW rabbits three-
times daily (TID) for 3 days, with a single additional drop instilled
on the morning of Day 4 (drug instillation at 8-h intervals). Animals
were euthanized (n¼ 4 at each time point) at 0.5, 1, 2, 3, 4, 8, 12 and
24 h post-dose. As with single-dose rabbits, blood samples were
collected for plasma analysis, followed by euthanasia and ocular
tissue harvesting.
In the single-dose group, aqueous humor, conjunctiva, cornea,
ICB and vitreous humor were collected from the dosed right eye,
whereas sclera, choroid and retina were collected from both dosed
and fellow undosed left eye. Sclera, choroid and retina were sub-
sampled as follows: 1) a band approximately bordered by the ora
serrata and equator (OS-E), and 2) the area posterior to the equator,
including the posterior pole (E-PP). In the repeated-dose group,
retina was collected in an identical fashion. E-PP sub-samplings
include central retina and choroid.
2.3.2. Ocular distribution study: monkeys
A single 30-mL drop of nepafenac 0.3% ophthalmic suspension
was instilled in the cul-de-sac of the right eyes of a total of 10
cynomolgus monkeys (2 per time point  5 time points) TID for 7
days, with a single additional drop instilled on the morning of Day
8. On Day 1 through Day 4, the study drug was instilled at 4-
h intervals to allow for dosing within an approximate normal
workday; on Day 5 through Day 7, the study drug was instilled at 8-
h intervals, adjusting to equal dose intervals. On Day 8, the animals
were euthanized (two at each time point) at 0 (trough), 0.25, 1, 2
and 3 h post-dose. Blood samples were obtained for the measure-
ment of nepafenac and amfenac plasma concentrations immedi-
ately prior to euthanizing the animals at each time point. Following
euthanasia, the dosed and fellow undosed eyes from each animal
were enucleated and dissected.
Collection and ocular tissues and ﬂuids and sub-sampling were
similar to that for rabbit groups, with the exception that vitreous
humor was harvested from both dosed and undosed eyes, and
sclera was additionally sub-sampled in a band approximately
bordered by the limbus and ora serrata (L-OS).
2.4. Assessments
2.4.1. Analysis of nepafenac and amfenac concentrations
All harvested samples, including plasma, were weighed and
stored frozen at 80 C until analysis. Nepafenac and amfenac
concentrations in ocular tissues, ﬂuids and plasma were deter-
mined by a high-performance liquid chromatography (HPLC)/tan-
dem mass spectrometry (LC/MS/MS) procedure. Plasma, aqueous
humor, and homogenates of ocular tissues (in HPLC-grade water)
were spiked with the pentadeuterated (d-5) analogs of nepafenac
and amfenac as internal standards and buffered with 1 mL of 0.1 M
sodium phosphate buffer (pH 6.5). The buffered homogenates were
extracted with reverse-phase solid-phase extraction cartridges
(StrataX, Phenomenex, Torrance, CA) and subsequently washed
with 1mL of 5%methanol inwater, and thenwith 1 mL of n-hexane
to remove endogenous interferences. Nepafenac and amfenac were
then eluted using two 0.5 mL aliquots of methanol. The column
efﬂuent was evaporated to dryness and the residue was re-
suspended in 120 mL of 10% methanol in water. Separation was
performed on a dodecylsilica (C12) column (Synergi MAX,Phenomenex, Torrance, CA) using gradient elution, with mobile
phases consisting of 5 mM aqueous ammonium formate (pH 8.0)
and methanol. The column efﬂuent was subjected to electrospray
ionization using the positive ion mode for nepafenac, and the
negative ion mode for amfenac. The protonated (nepafenac) and
deprotonated (amfenac) molecular ions were subjected to colli-
sional fragmentation using nitrogen to give characteristic product
ions for quantitation. Detection was achieved by selective reaction
monitoring of the m/z transitions 255 / 210, 260 / 215,
254/ 210, and 259/ 215 for nepafenac, d5-nepafenac, amfenac,
and d5-amfenac, respectively. Quantitation of nepafenac and
amfenac was performed against a calibration curve consisting of
blank tissue homogenates spiked with known amounts of both
analytes and processed in the same manner as the samples. Con-
centrations of nepafenac and amfenac in evaluated tissues were
calculated on the basis of tissue weight (amount of nepafenac or
amfenac in tissue divided by the tissue weight).
2.4.2. Estimation of local delivery and distribution to posterior
segment
Nepafenac and amfenac measured in the posterior segment
tissues (choroid, retina and vitreous humor) and adjacent sclera are
potentially derived from both local ocular delivery and redistribu-
tion of systemically absorbed nepafenac and amfenac. This sys-
temic contribution is greater in smaller species, such as rabbit and
cynomolgus monkey, where the ratio of body weight to eye size is
much smaller than in humans (Maurice, 2002). To correct for this,
both the dosed right eye and the fellow undosed left eye were
assayed for nepafenac and amfenac. For each animal, the concen-
trations of nepafenac and amfenac obtained for the undosed eye
were subtracted from that obtained for the fellow dosed eye. This
represents the local absorption and distribution of the prodrug and
its active metabolite, and is considered representative of bioavail-
ability in the larger human species.
2.4.3. Pharmacokinetic parameter estimates
Pharmacokinetic parameters were calculated from
concentration-time data and yielded estimates for mean maximal
concentration (Cmax), time to reach Cmax (Tmax) and cumulative area
under the concentration-time curve from time 0e24 h
(AUC24 hrCum). AUC24 hrCum was inclusive of AUC resulting from all
doses for a given day, i.e. single daily dose or three-times daily.
Pharmacokinetic parameters were calculated using Enterprise
Pharmacology/Kinetica software (version 4.2.1/5.1., ThermoFisher
Scientiﬁc, Waltham, MA). Nonquantiﬁable concentrations were
imputed to one-half the lower limit of quantitation (LLOQ), which
was 0.01 ng per tissue sample or 0.01 ng/mL for aqueous humor and
plasma. Normalized for tissue weight, LLOQ values ranged from
0.075 to 0.90 nM in the rabbit studies, and from 0.051 to 2.4 nM in
themonkey study. Concentrations in ng/mL or ng/g were converted
to nM assuming a density of 1 g per mL.
3. Results
3.1. Rabbit study
After a single topical ocular dose of nepafenac 0.1% ophthalmic
suspension, measurable concentrations of both nepafenac and
amfenac were achieved in the conjunctiva, cornea, ICB, and
aqueous humor of the dosed rabbit eyes. Speciﬁcally, mean peak
nepafenac concentrations between 1760 and 4960 nM were ach-
ieved in these anterior tissues within 0.25 h following drug instil-
lation, with the highest concentrations associated with cornea and
conjunctiva, which were in direct contact with the instilled dose
(Table 1). Mean peak amfenac concentrations between 111 and
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half-lives of nepafenac and amfenac in ICB were 6.3 and 36.9 h,
respectively.
Nepafenac rapidly distributed locally to sclera, choroid and
retina, sub-sampled from the area posterior to the equator inclusive
of the posterior pole (E-PP), with peak concentrations of 55.1, 4.03,
and 2.72 nM, respectively, within 0.25 h following drug instillation
(Table 1; Fig. 1). A lag time was observed in the local distribution of
amfenac, as peak concentrations of 41.9, 3.10 and 0.765 nM,
respectively, in the same sub-samplings were achieved approxi-
mately 1e4 h following drug instillation. The peak levels of nepa-
fenac in the sclera, choroid, and retina sub-samplings from the
band bordered by the ora serrata and equator (OS-E), were sub-
stantially higher than the corresponding E-PP samplings at 714,
92.2 and 110 nM. Similar to nepafenac, corresponding OS-E sclera,
choroid and retina peak concentrations of amfenac werewell above
those for E-PP sub-samplings at 468, 44.9 and 10.9 nM.
In general, amongst the E-PP sub-samplings of posterior-
segment tissues and sclera, the highest peak concentrations of
nepafenac and amfenac were observed in sclera, followed by the
choroid and retina, and were higher in the corresponding more
anterior OS-E samplings (Fig. 2). The longest duration of quantiﬁ-
able nepafenac or amfenac was 48 h in OS-E and E-PP sub-
samplings of sclera, followed by the OS-E choroid at 24 h and E-
PP choroid at 12 h. In the dosed eye, peak concentrations of
nepafenac and amfenac were lowest in the vitreous humor at 0.463
and 0.309 nM, respectively. Additionally, the peak concentrations of
nepafenac achieved in the vitreous humor were 9.4- and 6.3-fold
lower, respectively, than that in the E-PP sub-sampling of choroid
and retina. The peak concentration of amfenac in the vitreous hu-
mor was 17-fold lower than in the E-PP choroid and 4.3-fold lower
than in the E-PP retina. Thus, a concentration gradient of both
nepafenac and amfenac from local distributionwas observed in the
dosed rabbit eyes, indicating a mass transfer of the analytes from
the anterior tissues of the eye to the posterior tissues and from the
sclera inward. The percent of the resulting mean local distribution
in the sclera, choroid and retina relative to total mean concentra-
tion in the dosed eye (local plus systemic contribution) ranged from
50.0% to 97.2% in the E-PP sub-samplings and 91.8%e99.8% in the
OS-E sub-samplings. This indicates that the majority of drug in theTable 1
Summary of distribution of nepafenac and amfenac in the anterior and posterior ocular
nepafenac 0.1% ophthalmic suspension.
Tissue Nepafenac OD (n ¼ 4)b
Cmax (nM) Tm
Mean SD
Aqueous Humor 1760 790 0.2
Conjunctiva 2940 1890 0.2
Cornea 4960 3070 0.2
ICB 1870 1020 0.2
Plasma 8.23 1.75 0.2
OS-E Scleraa 714 108 0.2
E-PP Scleraa 55.1 15.5 0.2
OS-E Choroida 92.2 60.5 0.2
E-PP Choroida 4.03 3.27 0.5
OS-E Retinaa 110 67 0.2
E-PP Retinaa 2.72 2.07 0.2
Vitreous Humor 0.463 0.167 0.2
Abbreviations: Cmax ¼ maximum observed concentration; h ¼ hour; ICB ¼ iris-ciliary
concentration was observed; OS-E is the sub-sampling from the band bordered by the o
equator and inclusive of the posterior pole.
a Locally-distributed nepafenac or amfenac concentrations, determined as the differe
distribution (versus systemically-derived) in sclera, choroid and retina ranged from 50
Undosed eye mean Cmax concentrations in sclera, choroid and retina were: 1.71, 2.03 an
b n ¼ 4, except n ¼ 3 for vitreous humor.dosed eye resulted from local distribution as opposed to distribu-
tion of drug from the systemic circulation.
Instillation of multiple topical doses of nepafenac 0.3%
ophthalmic suspension QD for 4 days, resulted in peak concentra-
tions of nepafenac and amfenac in both the OS-E and E-PP sub-
samplings of retina at 0.5 h numerically higher than with multi-
ple doses of nepafenac 0.1% ophthalmic suspension instilled TID for
3 days, with a single morning dose on Day 4 (Table 2). Nepafenac
cumulative 24-h exposure (AUC24 hrCum) in OS-E sub-samplings of
retina for the 0.3% group was numerically lower than that in the
0.1% dose group (mean ± SD: 790 ± 99.5 nM and 920 ± 109,
respectively), although overlapping standard deviations (SD) sug-
gest this difference may not be real. AUC24 hrCum in E-PP retina sub-
samplings in the dose groups were similar at 169 ± 28.5 and
162 ± 19.3 nM, respectively. With respect to amfenac, the cumu-
lative 24-h AUC values in these groups were similar in the OS-E
retina sub-samplings (mean ± SD: 243 ± 16.5 and 240 ± 12.2 nM,
respectively). In the E-PP sub-samplings of retina, the cumulative
24-h AUC of amfenac after the nepafenac 0.3% QD was 51% of that
with nepafenac 0.1% TID (mean ± SD: 70.9 ± 9.05 and
140 ± 4.94 nM, respectively).3.2. Monkey study
Multiple topical ocular doses of nepafenac 0.3% ophthalmic
suspension were administered to cynomolgus monkeys TID for 7
days with a single dose on Day 8. Peak mean nepafenac concen-
trations were achieved in conjunctiva, cornea, ICB and aqueous
humor of the dosed eyes at 0.25 h after the last dose (Table 3). Peak
mean amfenac concentrations in the same tissues were somewhat
lower than nepafenac and were achieved at 0.25 or 1 h after the last
drug instillation (Table 3). The highest concentrations were
observed in cornea and conjunctiva, which were in direct contact
with the instilled dose.
Nepafenac was distributed to the posterior segment and sclera
of the dosed eye, with peak concentrations of 1630, 514, and
307 nM achieved, respectively, in the E-PP sub-samplings of sclera,
choroid, and retina within 1 or 2 h(s) following drug instillation
(Table 3; Fig. 3). In contrast to the rabbit data, there was no time lag
in distribution of amfenac relative to nepafenac. Peak amfenactissues of New Zealand White rabbits administered a single topical ocular dose of
Amfenac OD (n ¼ 4)b
ax (h) Cmax (nM) Tmax (h)
Mean SD
5 116 41.0 2.00
5 4690 2110 0.25
5 1410 380 0.25
5 111 29 2.00
5 25.0 4.4 0.25
5 468 157 1.00
5 41.9 11.3 1.00
5 44.9 14.0 1.00
0 3.10 0.28 4.00
5 10.9 5.3 0.25
5 0.765 0.590 1.00
5 0.309 0.086 0.25
body; OD ¼ right eye (dosed eye in this study); Tmax ¼ time at which maximum
ra serrata and the equator; E-PP is the sub-sampling from the area posterior to the
nce between dosed and undosed fellow eye concentrations. The percent of local
.0 to 99.2% in the E-PP sub-samplings and 91.8e99.8% in the OS-E sub-samplings
d 2.73 nM nepafenac; 1.21, 4.69 and 0.715 nM amfenac.
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Fig. 1. Mean nepafenac (A) and amfenac (B) concentrations by local distribution in
dosed rabbit eyes. Footnote: Concentrations of nepafenac and amfenac by local dis-
tribution (LD) in sclera, choroid, retina and vitreous humor after instillation of a single
topical dose of nepafenac 0.1% ophthalmic suspension into the right eye of New Zea-
land White rabbits. Graphs present mean concentrations (N ¼ 4) at each time point
and the error bars represent the standard deviations. OS-E is the sub-sampling from
the band bordered by the ora serrata and the equator; E-PP is the sub-sampling from
the area posterior to the equator and inclusive of the posterior pole.
Fig. 2. Maximal mean concentration (Cmax) nepafenac (A) and amfenac (B) concen-
trations by local distribution in dosed rabbit eyes. Footnote: Maximal mean concen-
tration (Cmax) of nepafenac and amfenac by local distribution (LD) in sclera, choroid,
retina and vitreous humor after instillation of a single topical dose of nepafenac 0.1%
ophthalmic suspension into the right eye of New Zealand White rabbits. Graphs pre-
sent mean concentrations (N ¼ 4) and the error bars represent the standard deviations.
OS-E is the sub-sampling from the band bordered by the ora serrata and the equator;
E-PP is the sub-sampling from the area posterior to the equator and inclusive of the
posterior pole.
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same sub-samplings of the dosed eye within the same 1- to 2-
h time frame observed for nepafenac. In general, the highest con-
centrations of both nepafenac and amfenac were observed in the E-
PP sub-samplings of sclera, followed by the E-PP sub-samplings of
choroid and retina. Peak concentrations of both nepafenac and
amfenac were lowest in the vitreous humor of the dosed eye at 15.2
and 3.43 nM, respectively.
In undosed fellow eyes, mean peak concentrations of nepafenac
and amfenac in the E-PP sub-samplings of sclera, choroid and retina
(nepafenac: 99.7, 210 and 19.7 nM; amfenac: 7.36, 11.0 and 2.04 nM,
respectively) were generallymuch lower than those obtained in the
corresponding sub-samplings of the dosed eye (Table 3). Both
analytes were low in the vitreous humor of the undosed eye
(1.95 nM for nepafenac and 0.705 nM for amfenac, which were 7.8-
and 4.9-fold lower than corresponding levels in the dosed eye).
Similar to the rabbit results, themonkey results indicate that the
majority of drug in the dosed eye resulted from local distribution, asopposed to distribution of drug from the systemic circulation. The
contribution of local ocular distribution to drug exposures in the E-
PP sub-samplings of sclera, choroid and retina ranged from 75.1% to
96.9% for nepafenac and 51.5%e82.2% for amfenac. The corre-
sponding ranges in the OS-E sub-samplings of sclera, choroid and
retina were 90.8%e99.1% for nepafenac and 82.2%e98.7% for
amfenac.
The Cmax values of the local distribution of nepafenac and
amfenac in the OS-E and E-PP sub-samplings of the sclera, choroid,
and retina, as well as in the vitreous humor, are shown in Fig. 4.
Overall, the Cmax values for nepafenac and amfenac in the more
anterior OS-E sub-samplings of sclera, choroid, and retina
were higher than those in the respective E-PP sub-samplings.
Table 2
Summary of ocular distribution of nepafenac and amfenac in the retina of New ZealandWhite rabbits administeredmultiple topical ocular doses of nepafenac 0.1% TID and 0.3%
QD ophthalmic suspension.
Tissue Nepafenac treatment Nepafenac LD Amfenac LD
Cmax (nM) AUC24 hrCum
(nMah)
Tmax (h) Cmax (nM) AUC24 hrCum
(nMah)
Tmax (h)
Mean SD Mean SD Mean SD Mean SD
OS-E Retina 0.1% TID 277 123 920 109 0.5 40.7 18.8 240 12.2 0.5
0.3% QD 645 340 790 99.5 0.5 80.3 41.1 243 16.5 0.5
E-PP Retina 0.1% TID 36.8 15.8 162 19.3 0.5 13.6 6.93 140 4.94 0.5
0.3% QD 88.1 57.8 169 28.5 0.5 25.5 12.5 70.9 9.05 1.0
Abbreviations:AUC24 hrCum ¼ area under the curve cumulative from 0 to 24 h, with TID total AUC derived from simulating full day concentration-time curves, based on post-
last dose data; Cmax¼maximum observed concentration; LD¼ local distribution; QD¼ once daily; TID¼ three times daily; Tmax¼ time at which maximum concentration was
observed; SD ¼ standard deviation; h ¼ hour; OS-E is the sub-sampling from the band bordered by the ora serrata and the equator; E-PP is the sub-sampling from the area
posterior to the equator and inclusive of the posterior pole.
a Locally-distributed (LD) nepafenac or amfenac concentrations, determined as the difference between dosed and undosed fellow eye concentrations.
J.E. Chastain et al. / Experimental Eye Research 145 (2016) 58e67 63Thus, an anterior-to-posterior concentration gradient of both
nepafenac and amfenac from local distributionwas observed in the
dosed monkey eyes. Further, the Cmax ranking was sclera >
choroid > retina > vitreous humor, indicating an inward distribu-
tion pattern, and conﬁrming that vitreous is not the site of initial
distribution in the posterior segment.
4. Discussion
Ocular penetration and potency are key components of the
success of an ophthalmic drug. However, anatomical and physio-
logical features of the eye such as blood ﬂow, metabolism, and the
presence of membrane receptors/transporters and intercellular
tight junctions present unique challenges for the delivery of a
topically administered drug to the anterior segment and, evenmore
so, to the tissues of the posterior segment (Ahmed and Patton,
1985; Koevary, 2003; Maurice and Mishima, 1986; Maurice, 2002).
The objectives of the animal studies reported in this paper were
to evaluate the contribution of local ocular delivery to the
bioavailability of topical ocular nepafenac and its active metabolite
amfenac in the posterior segment tissues of the eye, and to expand
understanding of the distribution pathways of these molecules.Table 3
Summary of ocular distribution of nepafenac and amfenac in dosed and undosed eyes o
ophthalmic suspension (n ¼ 2).
Tissue Nepafenac OD Nepafenac OS Nepafena
Cmax (nM) Tmax (h) Cmax (nM) Tmax (h) Cmaxa (nM) Tmax (h)
Aqueous Humor 2020 0.25 ND ND ND ND
Con-junctiva 18,200 0.25 ND ND ND ND
Cornea 12,700 0.25 145 2.00 12,600 0.25
ICB 5350 0.25 71.9 0.25 5280 0.25
Plasma 29.6 0.25 ND ND ND 0.25
L-OS Sclera 7170 0.25 46.2 2.00 7140 0.25
OS-E Sclera 2260 0.25 79.6 3.00 2240 0.25
E-PP Sclera 1630 2.00 99.7 0.25 1580 2.00
OS-E Choroid 1920 2.00 506 3.00 1830 2.00
E-PP Choroid 514 2.00 210 1.00 386 2.00
OS-E Retina 376 1.00 50.5 2.00 364 1.00
E-PP Retina 307 1.00 19.7 0.25 292 1.00
Vitreous Humor 15.2 2.00 1.95 1.00 13.8 2.00
Abbreviations: Cmax ¼maximum observed concentration; h ¼ hour; ICB ¼ iris-ciliary bo
study); OS ¼ left eye (undosed fellow eye in this study); Tmax ¼ time at which maximum c
limbus and the ora serrata; OS-E is the sub-sampling from the band bordered by the or
equator and inclusive of the posterior pole.
a The local distribution (LD) Cmax of nepafenac or amfenac was calculated by averag
centration was determined by subtracting the concentration in the undosed eye (attribu
local and systemic delivery).
b The percentage contribution of local distribution of nepafenac or amfenac to sclera, ch
eye Cmax of the respective matrix.Nepafenac and amfenac were found to be rapidly distributed into
the posterior segment tissues of rabbit and monkey eyes after the
unilateral topical ocular instillation of nepafenac 0.1% or nepafenac
0.3% ophthalmic suspension. In particular, these studies have
shown that drug delivery to the posterior segment tissues of the
eye is predominantly through local ocular routes. The uptake and
distribution of nepafenac and amfenac in the anterior segment
tissues observed in here was consistent with known penetration
pathways, such as through the cornea or conjunctiva/sclera. Passive
diffusion across the cornea and conjunctiva epithelium is driven by
the concentration gradient between the tear ﬁlm and drug con-
centrations in these tissues (Koevary, 2003; Maurice, 2002). In vitro,
nepafenac has been shown to exhibit a time- and concentration-
dependent permeation across the corneal and conjunctival
epithelia (Ke et al., 2000).
In the multiple-dose study in rabbits with 0.3% nepafenac
instilled once-daily or 0.1% nepafenac instilled three-times daily,
cumulative 24-h locally-distributed levels of nepafenac in E-PP
retina were similar between these groups, whereas exposure to
amfenac once-daily dosing nepafenac 0.3% was 51% of that ach-
ieved with three-times daily dosing of 0.1%. These results indicate
that 0.3% QD and 0.1% TID can locally deliver nepafenac andf cynomolgus monkeys administered a single topical ocular dose of nepafenac 0.3%
c LD Amfenac OD Amfenac OS Amfenac LD
%b Cmax (nM) Tmax (h) Cmax (nM) Tmax (h) Cmaxa (nM) Tmax (h) %b
ND 562 1.00 ND ND ND ND ND
ND 1990 0.25 ND ND ND ND ND
99.2 4820 1.00 10.1 2.00 4810 1.00 99.8
98.7 443 1.00 13.5 1.00 429 1.00 96.8
ND 23.9 1.00 ND ND ND 1.00 ND
99.6 890 0.25 6.42 1.00 887 0.25 99.7
99.1 392 1.00 4.65 1.00 387 1.00 98.7
96.9 26.7 2.00 7.36 1.00 21.3 2.00 79.8
95.3 85.9 2.00 29.0 3.00 78.4 2.00 91.3
75.1 22.9 1.00 11.0 1.00 11.8 1.00 51.5
96.8 19.7 2.00 2.50 1.00 17.6 2.00 89.3
95.1 3.58 2.00 2.04 1.00 2.58 2.00 72.1
90.8 3.43 2.00 0.71 1.00 2.82 2.00 82.2
dy; LD ¼ local distribution; ND ¼ not determined; OD ¼ right eye (dosed eye in this
oncentration was observed L-OS is the sub-sampling from the band bordered by the
a serrata and the equator; E-PP is the sub-sampling from the area posterior to the
ing individual animal LD concentrations at the LD Tmax. Individual animal LD con-
ted to systemic redistribution) from that in the fellow dosed eye (a combination of
oroid, retina and vitreous humor was obtained by dividing the LD Cmax by the dosed
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Fig. 3. Mean nepafenac (A) and amfenac (B) concentrations by local distribution in
dosed monkey eyes. Footnote: Concentrations of nepafenac and amfenac by local
distribution (LD) in sclera, choroid, retina and vitreous humor after repeated topical
instillations of nepafenac 0.3% ophthalmic suspension into the right eye of cynomolgus
monkeys. Graphs present mean concentrations (N ¼ 2) at each time point. L-OS is the
sub-sampling from the band bordered by the limbus and the ora serrata; OS-E is the
sub-sampling from the band bordered by the ora serrata and the equator; E-PP is the
sub-sampling from the area posterior to the equator and inclusive of the posterior pole.
Fig. 4. Maximal mean concentration (Cmax) nepafenac (A) and amfenac (B) concen-
trations by local distribution in dosed monkey eyes. Footnote: Maximal mean con-
centration (Cmax) of nepafenac and amfenac by local distribution (LD) in sclera,
choroid, retina and vitreous humor after repeated topical instillations of nepafenac
0.3% ophthalmic suspension into the right eye of cynomolgus monkeys. Graphs present
mean concentrations (N ¼ 2). L-OS is the sub-sampling from the band bordered by the
limbus and the ora serrata; OS-E is the sub-sampling from the band bordered by the
ora serrata and the equator; E-PP is the sub-sampling from the area posterior to the
equator and inclusive of the posterior pole. For each animal, the concentration of
nepafenac or amfenac obtained for the undosed eye was subtracted from that obtained
for the fellow dosed eye, thereby providing a measure of local distribution (LD) of the
compounds in the dosed eye through intraocular pathways other than systemic de-
livery. The individual concentrations were then averaged to provide the mean LD
concentrations.
J.E. Chastain et al. / Experimental Eye Research 145 (2016) 58e6764amfenac from a topical dose, with drug exposures in the retina that
are similar or within 50% of each other. It is noted that besides
differing in nepafenac concentration, the 0.1% and 0.3% formula-
tions differed in some excipients. Mannitol and tyloxapol were
present in the 0.1% suspension, but not the 0.3% suspension,
whereas the 0.3% suspension contained boric acid, propylene gly-
col, guar gum, and carboxy methylcellulose, which were not com-
ponents of the 0.1% suspension. Shared excipients included
carbomer 974P, edetate disodium, benzalkonium chloride (preser-
vative) and sodium chloride. The compositions of the 0.1% and 0.3%
formulations were identical to their respective marketed products.
The increase in ocular bioavailability with 0.3% compared to 0.1%
nepafenac, leading to similar daily drug exposure, resulted from the
combined impact of differences in nepafenac concentration and
excipients since ILEVRO has a proprietary viscosity systemdesigned
to enhance ocular retention and contribute to increased nepafenac
bioavailability. However, the respective contributions of nepafenac
concentration and excipients to the results presented were not
speciﬁcally determined.The pathways for distribution of topical drugs to the back of the
eye are not as well characterized. One proposed pathway to the
posterior segment is through the cornea, anterior chamber, lens,
pupil, iris or iris root, with drug distribution targeting the vitreous
humor (Koevary, 2003; Maurice, 2002). However, this pathway is
considered the least probable because it generally involves drug
movement upstream against aqueous humor ﬂow, and evidence
J.E. Chastain et al. / Experimental Eye Research 145 (2016) 58e67 65presented herein does not support signiﬁcant contribution of the
vitreous humor to posterior drug distribution. Although the re-
ported rabbit and monkey studies demonstrated high concentra-
tions of nepafenac and amfenac in the ICB, the low and short-lived
concentrations of both analytes in the vitreous humor indicate that
it is unlikely to serve as a drug reservoir or pathway for drug dis-
tribution. This does not discount the possibility of transcorneal
penetration into the anterior chamber, with distribution to the
sclera by an outﬂow mechanism and subsequent periorbital
anterior-to-posterior distribution. However, mechanistic data are
currently lacking to support or refute this route.
An alternative, and more probable, uptake pathway to the
posterior segment from a topical dose is through the conjunctiva
and underlying sclera, followed by distribution across the choroid
and retinal pigment epithelium (RPE) (Koevary, 2003; Maurice,
2002). Investigations using scleral and periocular implants to take
advantage of the transcleral route have been recently evaluated for
drugs including betamethasone, celecoxib, and anti-angiogenic
agents (Amrite et al., 2006; Cruysberg et al., 2005; Okabe et al.,
2007). It has been suggested that for drugs to passively diffuse
through the sclera and choroid and permeate the RPE, a sustained
concentration gradient would be required to drive this process
(Hughes et al., 2005). In fact, the studies reported here demonstrate
high and sustained levels of nepafenac and amfenac in sclera and
choroid following topical ocular nepafenac instillation.
In the animal studies reported here, an appreciable concentra-
tion gradient was observed between the anterior and posterior
segment tissues (Tables 1e3) and between the OS-E and E-PP sub-
samplings of sclera, choroid, and retina (Figs. 2 and 4), indicating an
anterior-posterior transfer of drug within the eye; this gradient was
sustained for many hours after even a single topical ocular dose
(Figs. 1 and 3). Although sustained levels were seen in the sclera,
the possibility of longitudinal distribution of drug within the sclera
to the posterior segment and macular region as a key component is
unlikely as movement of drug by this means is very slow. For
example, diffusion from the front of the eye to about halfway along
the sclera for about 10 mm has been calculated to require about 3
days (Jiang et al., 2006), whereas evidence presented here
demonstrated rapid distribution to the retina in as little as 15 min.
This suggests the presence of a different anterior-to-posterior
pathway, not necessarily through the longitudinal sclera.
In the posterior segment tissues of rabbits administered a single
topical dose of nepafenac, the distribution pattern was similar for
nepafenac and its metabolite amfenac (Table 1 and Fig. 2). In
monkeys this relationship was somewhat less evident (Table 3 and
Fig. 4), possibly due to species-related differences in amidase hy-
drolysis rates. In both rabbits and monkeys, nepafenac concentra-
tions were higher than amfenac concentrations in all ocular tissues
except rabbit conjunctiva. The higher nepafenac versus amfenac
levels likely reﬂected a slower rate of hydrolysis than distribution of
parent drug, nepafenac, to the back of the eye. The reason for higher
amfenac than nepafenac levels in rabbit conjunctiva, as well as
plasma, is unknown, but could be related to faster enzymatic hy-
drolysis in conjunctiva, or, in the case of plasma, faster intestinal or
liver hydrolysis associated with systemic absorption or clearance.
Based on the results of the animal studies described here, we
propose a route for the distribution of nepafenac and amfenac to
the posterior segment tissues that involves drug transfer to the
sclera, choroid, and retina via a transconjunctival/scleral route of
absorption, with subsequent anterior-to-posterior movement,
possibly involving the choroid or suprachoroidal space. An alter-
native periocular pathway is possible, involving drug in the tear
ﬂuid penetrating into conjunctival fornices, with rapid drug pene-
tration across the bulbar conjunctiva into the sclera and orbit, fol-
lowed by penetration into the retina (Maurice, 2002). It isnoteworthy that the conjunctival fornices extend to the equator,
giving topical drug signiﬁcant retrobulbar access. Both routes rely
on the concentration gradient for nepafenac and amfenac, which is
dependent on amfenac and nepafenac diffusion, and also on the
hydrolysis of distributed nepafenac to amfenac by tissue amidases.
Ex vivo studies have shown high levels of amidases in ocular tissues
obtained from rabbit and human eyes, with the rank order of
retina/choroid >> ICB > cornea (Ke et al., 2000). Results from the
current studies demonstrate that nepafenac readily permeates and
distributes to both anterior and posterior segment tissues (i.e. ICB,
choroid/retina), and is rapidly converted to amfenac.
Drug delivery to the fellow undosed eye is understood to occur
via systemic circulation. In the undosed eye, a concentration
gradient consistent with the blood ﬂow in the eye was observed,
with the highest concentration seen in the highly vascularized
choroid, followed by the sclera and retina. The lowest concentra-
tions of nepafenac and amfenac were observed in the vitreous
humor. Therefore, comparing the concentration gradients and drug
levels between the posterior segment tissues of the treated and
untreated eyes indicates that the net pathway for drug transfer in
the dosed eye is through local distribution pathways.
Many topically administered drugs have been shown to reach
the posterior segment tissues via diffusion from the systemic cir-
culation (Koevary, 2003; Maurice, 2002). The fraction of the topical
ocular dose that is available in the systemic circulation reﬂects
species differences in body weight (e.g. volume of distribution).
Speciﬁcally, in small animals, the drug distribution through the
systemic circulation may be signiﬁcant. To account for the contri-
bution of local versus systemic distribution, the analyte concen-
tration in the fellow undosed eye (systemic contribution) was
subtracted from the dosed eye (systemic plus local contribution).
The high drug concentration levels contributed by local distribution
in the current studies reﬂect the appreciable distribution of both
nepafenac and amfenac through local pathways. At similar topical
ocular doses, the plasma concentrations of nepafenac in humans
are much lower than in rabbits and monkeys (NEVANAC® Product
Monograph). The reported plasma mean maximal concentrations
of nepafenac and amfenac following bilateral topical instillation of
NEVANAC 0.1% in humans were 0.310 ng/mL and 0.422 ng/mL,
respectively. Accounting for unilateral dosing in the animals, these
values are 13-folde39-fold lower than observed in rabbits and
monkeys, respectively. The contribution of drug distribution from
systemic circulation to the posterior segment following topical
ocular administration is therefore expected to be much smaller in
humans than in rabbits and monkeys.
The high and sustained concentrations of nepafenac in the ICB,
sclera, choroid and retina observed in this study (Figs. 1 and 3)
would also be expected to provide a signiﬁcant source of amfenac
via hydrolysis. Importantly, in the eye, COX activity is most abun-
dant in the ICB, and lower, but meaningful, levels are found in the
retina (Kulkarni and Srinivasan, 1989). Studies have shown that
nepafenac and amfenac signiﬁcantly and reversibly inhibit both
COX-1 and COX-2, while amfenac also potently inhibits both iso-
forms of COX, but especially COX-2, in a time-dependent, essen-
tially irreversible manner (Gamache et al., 2000; Kulmacz and
Graff, 2007; Walters et al., 2007). COX-1 is a constitutive, “house-
keeping” enzyme regulating basal production of prostaglandins for
normal cellular function, while COX-2 is an inducible enzyme with
a proinﬂammatory role (Turini and DuBois, 2002; Masferrer and
Kulkarni, 1997). In the current studies, the concentrations of
amfenac in the retina of both the rabbit and the monkey
(Tables 1e3) were within the IC50 range of 1.77e150 nM for COX-2
inhibition reported by Gamache et al. (2000) and Walters et al.
(2007), and therefore would be expected to potently inhibit pros-
taglandin production. At the same time, amfenac levels in the retina
Fig. 5. Proposed schematic for the transfer of nepafenac and amfenac to the posterior
segment tissues following the topical instillation of nepafenac ophthalmic suspension.
Blue and green arrows represent periocular and choroid/suprachoroidal pathways,
respectively. Orange arrows represent inward distribution through sclera, choroid and
retina.
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inhibition reported by the same researchers, but did approach
this range with levels as high as 80.3 nM, suggesting some contri-
bution from COX-1 inhibition.
With regard to nepafenac inﬂuence on prostaglandin produc-
tion, in the current monkey study, the mean concentration of
locally-distributed nepafenac in the OS-E choroid sub-sampling
was as high as 1830 nM, which was similar to the Ki value of
2300 nM for COX-1 inhibition reported by Kulmacz and Graff
(2007). However, nepafenac levels in the E-PP choroid, OS-E
retina and E-PP retina sub-samplings (386, 364 and 292 nM,
respectively), while meaningful, were below the Ki, suggesting that
in these tissues the inhibition of prostaglandin synthesis was
mainly due to amfenac, with some contribution from nepafenac.
Overall, the results of the current studies indicate that pharmaco-
logically relevant nanomolar concentrations of both nepafenac and
amfenac were achieved in the posterior segment tissues of the eye.
The COX inhibitory activity of both nepafenac and amfenac in the
posterior segment tissues, as discussed above, should be sufﬁcient
to locally inhibit prostaglandin E2 production. This has been shown
in a rabbit model of mitogen-induced pan-retinal edema, in which
treatment with topical nepafenac resulted in a 65% reduction in
retinal edema with a near complete suppression of prostaglandin
E2 synthesis (Kapin et al., 2003).
The data obtained from the current studies support the duration
of activity reported previously in animal efﬁcacy model studies.
These studies have shown that topical ocular administration of
nepafenac signiﬁcantly inhibits prostaglandin H synthase in the
retina/choroid and ICB ex vivo for up to 6 h post-dose, and has
potent anti-inﬂammatory activity for up to 8 h post-dose in a rabbit
model of trauma-induced ocular inﬂammation (Gamache et al.,
2000).
The results of the current rabbit and monkey studies also show
that drug delivery to the posterior segment tissues occurs pre-
dominantly via local pathways in the eye. Further, based on the
observed concentration gradient across the tissues of the posteriorsegment, it appears that the pathway for local distribution of
nepafenac and amfenac to the central retina and choroid (included
in E-PP sub-samplings) does not signiﬁcantly involve the vitreous
humor. In addition, the observed sustained concentrations of
nepafenac in the posterior segment of the eye further suggest the
presence of a reservoir of nepafenac that would provide a source for
continued nepafenac and amfenac exposure. This is consistent with
the results of human clinical studies, which have shown that
nepafenac ophthalmic suspensions, 0.1% TID and 0.3% QD, are
effective for the treatment of pain and inﬂammation associated
with cataract surgery (Lane et al., 2007; Nardi et al., 2007; Modi
et al., 2014). In addition, topical nepafenac 0.1% showed signiﬁ-
cant and clinically relevant prevention of macular edema in pa-
tients with diabetes, following cataract surgery (Singh et al., 2012).
Given the complete results of the current rabbit and monkey
studies, a pathway for the distribution of nepafenac and amfenac to
the posterior segment tissues is proposed that most likely involves
the distribution of these molecules along an anterior-to-posterior
pathway via choroid/suprachoroidal or periocular route and in-
ward through the sclera, followed by choroid, and retina (Fig. 5).
Involvement of the vitreous appears to be minimal in the distri-
bution of topical drug to the back of the eye.
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